Diathrive Health, a diabetes and chronic disease management solution, and Mark Cuban Cost Plus Drug Company have announced a new collaboration, focused on improving healthcare access, lowering costs, and improving outcomes for people living with diabetes and other chronic diseases.
Why does it matter?
Cost Plus Drugs and Diathrive Health are both industry disruptors. The relationship will give consumers lower-cost medications and diabetes testing supplies and more personalized, higher-quality care so that they can achieve better health outcomes.
Diathrive Health removes the financial, administrative and psychosocial barriers to managing a chronic condition. Members get unlimited diabetes testing supplies, clinical support from nurses who are Certified Diabetes Care and Education Specialists (CDCES) and access to the Diathrive Health app that enables users to self-educate and train themselves on how to manage their condition.
On the record
“As a practicing physician I saw first-hand the danger of patients not being able to afford medications and supplies,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “I founded the Mark Cuban Cost Plus Drug Company to help solve this problem and provide a way for patients to receive their treatments at an affordable price. We already offer transparent, low prices to cash-pay consumers and are excited to now be working with a company like Diathrive Health to further reduce the cost to patients, and to keep the patient record complete from both a clinical and financial perspective.”
“Chronic diseases like diabetes are complex. The partnership with Cost Plus Drugs will give our customers another piece of the puzzle. Diathrive Health is happy to work with a company and team who share our goals and values,” said Michael Hennessy, Founder and CEO of Diathrive Health.
Prescription drugs in the US cost about 2.5 times what they do in other countries, and a quarter of Americans find it difficult to afford them. Almost every new cancer drug starts at over $100,000 a year. And a 2022 study found that every year, the average price of newly released drugs is 20% higher. So, yes, this partnership makes a lot of sense.